• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于改良对比增强超声 LI-RADS M 标准的多参数肝内胆管细胞癌评分系统,用于鉴别肝内胆管细胞癌与肝细胞癌。

A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

机构信息

Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, 200032, China.

Shanghai Institute of Medical Imaging, Shanghai, 200032, China.

出版信息

Abdom Radiol (NY). 2024 Feb;49(2):458-470. doi: 10.1007/s00261-023-04114-6. Epub 2024 Jan 16.

DOI:10.1007/s00261-023-04114-6
PMID:38225379
Abstract

PURPOSE

To develop a multi-parameter intrahepatic cholangiocarcinoma (ICC) scoring system and compare its diagnostic performance with contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system M (LR-M) criteria for differentiating ICC from hepatocellular carcinoma (HCC).

METHODS

This retrospective study enrolled 62 high-risk patients with ICCs and 62 high-risk patients with matched HCCs between January 2022 and December 2022 from two institutions. The CEUS LR-M criteria was modified by adjusting the early wash-out onset (within 45 s) and the marked wash-out (within 3 min). Then, a multi-parameter ICC scoring system was established based on clinical features, B-mode ultrasound features, and modified LR-M criteria.

RESULT

We found that elevated CA 19-9 (OR=12.647), lesion boundary (OR=11.601), peripheral rim-like arterial phase hyperenhancement (OR=23.654), early wash-out onset (OR=7.211), and marked wash-out (OR=19.605) were positive predictors of ICC, whereas elevated alpha-fetoprotein (OR=0.078) was a negative predictor. Based on these findings, an ICC scoring system was established. Compared with the modified LR-M and LR-M criteria, the ICC scoring system showed the highest area under the curve (0.911 vs. 0.831 and 0.750, both p<0.05) and specificity (0.935 vs. 0.774 and 0.565, both p<0.05). Moreover, the numbers of HCCs categorized as LR-M decreased from 27 (43.5%) to 14 (22.6%) and 4 (6.5%) using the modified LR-M criteria and ICC scoring system, respectively.

CONCLUSION

The modified LR-M criteria-based multi-parameter ICC scoring system had the highest specificity for diagnosing ICC and reduced the number of HCC cases diagnosed as LR-M category.

摘要

目的

开发一种多参数肝内胆管细胞癌(ICC)评分系统,并将其与对比增强超声(CEUS)肝脏成像报告和数据系统 M(LR-M)标准区分 ICC 与肝细胞癌(HCC)的诊断性能进行比较。

方法

本回顾性研究纳入了 2022 年 1 月至 12 月期间来自两个机构的 62 名高危 ICC 患者和 62 名高危 HCC 患者。通过调整早期洗脱起始(<45 s)和明显洗脱(<3 min)来修改 CEUS LR-M 标准。然后,基于临床特征、B 型超声特征和修改后的 LR-M 标准建立了多参数 ICC 评分系统。

结果

我们发现,CA 19-9 升高(OR=12.647)、病变边界(OR=11.601)、周边边缘状动脉期高增强(OR=23.654)、早期洗脱起始(OR=7.211)和明显洗脱(OR=19.605)是 ICC 的阳性预测因素,而甲胎蛋白升高(OR=0.078)是阴性预测因素。基于这些发现,建立了 ICC 评分系统。与修改后的 LR-M 和 LR-M 标准相比,ICC 评分系统的曲线下面积(0.911 与 0.831 和 0.750,均 p<0.05)和特异性(0.935 与 0.774 和 0.565,均 p<0.05)最高。此外,使用修改后的 LR-M 标准和 ICC 评分系统,LR-M 分类的 HCC 数量分别从 27 例(43.5%)减少至 14 例(22.6%)和 4 例(6.5%)。

结论

基于修改后的 LR-M 标准的多参数 ICC 评分系统对诊断 ICC 具有最高的特异性,并减少了被诊断为 LR-M 类别的 HCC 病例数量。

相似文献

1
A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.基于改良对比增强超声 LI-RADS M 标准的多参数肝内胆管细胞癌评分系统,用于鉴别肝内胆管细胞癌与肝细胞癌。
Abdom Radiol (NY). 2024 Feb;49(2):458-470. doi: 10.1007/s00261-023-04114-6. Epub 2024 Jan 16.
2
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
3
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.
4
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.超声造影肝脏影像报告与数据系统:在肝细胞癌和胆管细胞癌诊断中的优缺点。
World J Gastroenterol. 2022 Jul 21;28(27):3488-3502. doi: 10.3748/wjg.v28.i27.3488.
5
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.
6
Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.动态对比增强超声在非肝硬化肝脏肝细胞癌和肝内胆管细胞癌鉴别诊断中的应用。
Ultrasound Med Biol. 2023 Aug;49(8):1780-1788. doi: 10.1016/j.ultrasmedbio.2023.03.026. Epub 2023 May 6.
7
Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.超声造影联合血清生物标志物鉴别肝细胞胆管癌与肝细胞癌及肝内胆管癌
World J Gastroenterol. 2020 Dec 14;26(46):7325-7337. doi: 10.3748/wjg.v26.i46.7325.
8
Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.对比增强超声在低分化肝细胞癌与肝内胆管癌鉴别诊断中的应用
J Ultrasound Med. 2022 May;41(5):1213-1225. doi: 10.1002/jum.15812. Epub 2021 Aug 23.
9
Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.现行与改良 CEUS LI-RADS 在诊断非肝细胞癌恶性肿瘤中的表现。
Abdom Radiol (NY). 2023 Dec;48(12):3688-3695. doi: 10.1007/s00261-023-04043-4. Epub 2023 Sep 19.
10
LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.LR-M 超声造影观察:与当前 LI-RADS 标准相比,利用附加特征检测肝细胞癌。
AJR Am J Roentgenol. 2022 Jul;219(1):76-85. doi: 10.2214/AJR.21.26837. Epub 2021 Dec 15.

引用本文的文献

1
Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.超声造影诊断肝内胆管癌亚型:与低分化肝细胞癌的对比研究
Cancer Imaging. 2025 Aug 27;25(1):107. doi: 10.1186/s40644-025-00923-8.
2
Four overlooked errors in ROC analysis: how to prevent and avoid.ROC分析中四个被忽视的错误:如何预防与避免。
BMJ Evid Based Med. 2025 May 20;30(3):208-211. doi: 10.1136/bmjebm-2024-113078.

本文引用的文献

1
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.欧洲胆管癌全景:ENSCCA 注册中心的诊断、预后和治疗见解。
J Hepatol. 2022 May;76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010. Epub 2022 Feb 12.
2
Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017.使用新的标准提高 HCC 和非 HCC 恶性肿瘤的鉴别能力:CEUS LI-RADS 2017 的临床实践和讨论。
Radiol Med. 2022 Jan;127(1):1-10. doi: 10.1007/s11547-021-01417-w. Epub 2021 Oct 19.
3
Biliary tract cancer.
胆道癌。
Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7.
4
Role of Biomarkers and Biopsy in Hepatocellular Carcinoma.肝癌的生物标志物和活检的作用。
Clin Liver Dis. 2020 Nov;24(4):577-590. doi: 10.1016/j.cld.2020.07.001. Epub 2020 Aug 28.
5
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
6
Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma.甲胎蛋白对肝细胞癌发生发展的影响。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2439-2446. doi: 10.1007/s00432-020-03331-6. Epub 2020 Jul 28.
7
Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection.对比增强超声 LI-RADS 版本 2017 评估:在乙型肝炎感染患者的 2020 个肝脏结节中的应用。
Radiology. 2020 Feb;294(2):299-307. doi: 10.1148/radiol.2019190878. Epub 2019 Nov 26.
8
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.
9
Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence.根治性切除术后肝内胆管癌的特征:结局、预后因素及复发
BMC Gastroenterol. 2018 Dec 4;18(1):180. doi: 10.1186/s12876-018-0912-x.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.